Telix Pharmaceuticals Ltd — Capital/Financing Update 2024

Jul 29, 2024

Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [156 x 65] intentionally omitted <==

ASX ANNOUNCEMENT

Telix Announces Completion of A$650 Million Convertible Bonds

Melbourne (Australia) – 30 July 2024 . Further to announcements by Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company) on 23 and 24 July 2024, Telix is pleased to announce the completion of the issue of A$650 million 2.375 per cent convertible notes due 2029.

The convertible notes, also referred to as “convertible bonds” will be listed on the Official List of the Singapore Exchange Securities Trading Limited on 31 July 2024.

J.P. Morgan Securities Plc acted as Sole Manager on the offering.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix Investor Relations

Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Neither this announcement nor any copy hereof may be released, published or distributed in the United States. The information contained in this announcement is not for release, publication, or distribution, directly or indirectly, in or into the United States or to any other jurisdiction where such release, publication or distribution would be prohibited by applicable law.

This announcement is for information only and does not constitute or form part of any offer to purchase, a solicitation of an offer to purchase, an offer to sell or an invitation or solicitation of an offer to sell, issue or subscribe for any securities in the United States or any other jurisdiction. No recommendation with respect to shares or other securities of the Company is made hereby. Neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever.

The Convertible Bonds and the Ordinary Shares issuable upon conversion of the Convertible Bonds have not been and will not be registered under the Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Convertible Bonds or the Ordinary Shares issuable upon conversion of the Convertible Bonds will be made in the United States.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

Page 1